Full text not available from this repository.

Abstract

Background: Noneclear-cell renal cell carcinoma (nccRCC) and renal cell carcinoma with sarcomatoid features(scRCC) are rare, and represent subtypes with less defined treatment strategies. The aim of this study is to describethe patterns of care and outcomes of these patients in 2 tertiary referral centers in South Western Sydney Local HealthDistrict over a 10-year period. Patients and Methods: Patients with RCC seen at South Western Sydney Local HealthDistrict from January 1, 2005 to December 31, 2015 were identified from electronic medical records. For each patient,we extracted details regarding demographics, tumor characteristics, treatment, recurrences, and survival, which wasanalyzed using the Kaplan-Meier method. Results: Of 178 patients with RCC identified between 2005 and 2015, 23%(n ¼ 41) had nccRCC and 8% (n ¼ 15) had scRCC. Twenty-five patients in total had de novo metastatic disease ordisease recurrence. The median follow-up was 46 and 16 months for nccRCC and scRCC, respectively. The medianoverall survival for nccRCC with metastatic disease was 34 months (range, 14 months to not reached). Seventypercent of these patients received systemic therapy. By contrast, the median overall survival for scRCC withmetastatic disease was 10 months (range, 1.6-89 months). Less than one-half of the patients with scRCC receivedsystemic therapy in our cohort, with only 34% receiving no more than 1 line of treatment. Conclusions: Our dataconfirm the rapid and aggressive course of scRCC, highlighting the need for more effective therapeutic strategies inthis rare patient population.

Item Type:	Article
Authors/Creators:	Naher, S and Padinharakam, S and Balakrishnar, B and Chua, W and Descallar, J and Adams, D and de Souza, P and Harrison, M and Lim, S
Keywords:	outcomes, recurrence, renal carcinoma, systemic, treatment
Journal or Publication Title:	Clinical Genitourinary Cancer
Publisher:	Elsevier
ISSN:	1558-7673
DOI / ID Number:	10.1016/j.clgc.2019.02.006
Copyright Information:	Copyright 2019 Elsevier Inc. All rights reserved.
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page